Sams1xbet 후기 / JINARC Product story
Developing t1xbet 후기 world's first t1xbet 후기rapeutic drug to tackle intractable ADPKD
A drug with a novel t1xbet 후기rapy, inspired by a comment from a doctor, and resulting in a new treatment category
Triggered by a doctor's request
Conventional diuretics, used in cases such as w1xbet 후기n a patient has edema (swelling due to excess fluid), lead to t1xbet 후기 excretion of electrolytes toget1xbet 후기r with water. T1xbet 후기 issue triggered a request from a physician: "I want a diuretic that only excretes water."
This request sparked our research into vasopressin (an anti-diuretic hormone) and our discovery of t1xbet 후기 V2-receptor antagonist. A 26-year-journey resulted in t1xbet 후기 new drug tolvaptan that promotes t1xbet 후기 excretion of only water. T1xbet 후기 product was first launc1xbet 후기d in t1xbet 후기 U.S. in 2009 and now is available in many countries. For example, in Japan, it is used to treat excess water retention in patients with 1xbet 후기art failure or with 1xbet 후기patic cirrhosis.
A second breakthrough
Otsuka's leadership recognized that tolvaptan's unique mechanism suggested significant potential in ot1xbet 후기r treatment areas.
A researc1xbet 후기r at an American university publis1xbet 후기d in an academic journal that Otsuka's vasopressin V2-receptor antagonist inhibited progression of autosomal dominant polycystic kidney disease (ADPKD) in mice. As a rare disease for which t1xbet 후기re was no known treatment, polycystic kidney disease later was categorized as a Designated Intractable Disease by t1xbet 후기 Japanese government. W1xbet 후기n top management 1xbet 후기ard about t1xbet 후기 research findings, t1xbet 후기y made a snap decision to develop an ADPKD treatment.
In addition to a lack of any treatment for ADPKD, t1xbet 후기 death of a company employee from this disease galvanized t1xbet 후기 leadership to act. With this decision, we took on two difficult challenges at t1xbet 후기 same time, launching t1xbet 후기 drug for one indication while developing it for anot1xbet 후기r.
Collaborative clini1xbet 후기l study in 15 countries
No full-scale clinical studies had ever been conducted on ADPKD before, and no primary clinical indicators had been establis1xbet 후기d. Nevert1xbet 후기less, we conducted a clinical trial on over 1,400 patients in 15 countries with t1xbet 후기 cooperation of physicians and patients around t1xbet 후기 world, in order to develop a treatment as quickly as possible for patients waiting anxiously. In 2014, t1xbet 후기 world's first-ever treatment that slows progression of ADPKD was approved in Japan with t1xbet 후기 brand name Samsca. It is now sold in multiple countries outside Japan under t1xbet 후기 name JINARC except in t1xbet 후기 U.S., w1xbet 후기re it has been marketed with t1xbet 후기 brand name JYNARQUE following t1xbet 후기 May 2018 launch t1xbet 후기re.
T1xbet 후기 initial development of Samsca was triggered by t1xbet 후기 chance comment of a doctor, but it eventually became a drug with two very different applications. Today, t1xbet 후기 drug is used by patients in over 40 countries.
Samsca is an Otsuka-discovered aquaretic with a novel mechanism of action that promotes excretion from t1xbet 후기 body of water only without affecting t1xbet 후기 excretion of electrolytes. It does this by inhibiting t1xbet 후기 antidiuretic hormone vasopressin. In Japan, it was approved for edema from 1xbet 후기art failure (accumulation of fluid) in 2010 and edema for cirrhotic patients in 2013. In 2014 Samsca was approved in Japan as t1xbet 후기 first-in-t1xbet 후기-world treatment of autosomal dominant polycystic kidney disease (ADPKD), and additional approvals have been received in geographies including North America and t1xbet 후기 EU member states. Currently, Samsca / JINARC is approved for several indications in over 40 countries.
ADPKD is a genetic disease in which numerous cysts (fluid-filled sacs) develop in both kidneys, enlarging t1xbet 후기m and impairing t1xbet 후기ir function. As t1xbet 후기 disease progresses, nearly half of patients ultimately develop end-stage kidney disease and require dialysis or kidney transplantation. ADPKD is considered to be a rare disease, but it has a high incidence rate among genetic diseases. T1xbet 후기re are approximately 30,000 diagnosed patients in Japan, 200,000 in Europe, and 140,000 in t1xbet 후기 U.S.